Milan, 05.12.2018

NMS Group wins the Capital Elite - China Awards 2018

"A recognition of companies, entrepreneurs, professionals and Institutions that distinguished themselves in the relations between Italy and China." The thirteenth edition of the China Awards was held under the patronage of the Ministry of Foreign Affairs, the Ministry of Economic Development and the Italian-Chinese Chamber of Commerce and in partnership with the Italian Chamber of Commerce in China.
Read more +
New York/London, 03.12.2018

Tiziana Completes Patient Enrollment in a Phase 2a Trial to Evaluate Tolerability and Anti-Tumor Activity of Milciclib in Hepatocellular Carcinoma (HCC)

This is a single-arm, repeated-dose, 6-month duration study to evaluate safety, tolerability and anti-tumor activity of Milciclib in Sorafenib-refractory or -intolerant patients with unresectable or metastatic HCC. Topline data from this multi-center trial, being conducted in Italy, Greece and Israel, will be available in the second quarter of 2019.
Read more +
Nerviano, 07.09.2018

Nerviano Medical Sciences received a prestigious Marie Sklodowska-Curie Fellowship, under the EU Research and Innovation programme Horizon 2020

The prestigious grant is for a 24 months project with a high scientific target. It is to create a methodology platform providing the ability to design and synthesize arrays of Targeted Protein Degradation Inducers (TPDIs) and their advanced, adequately protected, precursor intermediates with the objective to induce tumoral cell death.
Read more +
Solna, 02.08.2018

Xspray Pharma and NerPharMa deliver clinical trial material to HyNap-Dasa study

Xspray Pharma reported that the first clinical trial material from NerPharMa S.r.l. has been delivered to the HyNap-Dasa clinical trial, the results of which are expected in Q3 2018. HyNap-Dasa is one of three product candidates that Xspray currently has in development. The company’s goal is to launch HyNap-Dasa on the US market in 2021.
Read more +
Nerviano, Italy, 01.06.2018

Nerviano Medical Sciences announces Collaboration and License Agreement with Merck to discover small molecule inhibitors of certain anticancer targets

Today Nerviano Medical Sciences, the largest pharmaceutical R&D facility in Italy and one of the leading oncology-focused, integrated discovery and development companies in Europe, announced an agreement with Merck, a leading science and technology company, under which the two companies will collaborate on the discovery of small molecule inhibitors of certain molecular targets in the area of DNA damage repair.
Read more +
Nerviano, Italy, 16.04.2018


Elena Ardini, a biologist at Nerviano Medical Sciences, is the first author of a scientific publication by our group selected for inclusion in this year’s "Best of the AACR Journals Collection". The article entitled “Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications” appeared in the AACR Journal “Molecular Cancer Therapeutics” in 2016 and became its most cited publication of that year. Entrectinib, a molecule discovered, developed and brought to the clinic by Nerviano Medical Scieces showcases the scientific excellence and drug discovery/development expertise of the Nerviano Campus.
Read more +
Nerviano, Italy, 05.04.2018

Nerviano Researchers’ Contribution in Building Anticancer Drug Actions Atlas

This is the most complete study carried out, up to date, on kinases and over 240 inhibitors and it illustrates how new opportunities for cancer treatment could arise from some kinase inhibitors already approved or currently in clinical development phase. Involved four experienced researchers from Nerviano Campus, highly regarded in the field of kinase biochemistry and structural chemistry.
Read more +
Nerviano, Italy, 28.03.2018


SARI, a Chinese market-leader biotech investment company, is pleased to announce that it has closed the previously announced agreement to acquire the 90% interests in NMS Group S.p.A., effective from today.
Read more +